Company Profile

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders.



Management Team

Senior Vice President, Development Operations
Chief Operating Officer
Senior Vice President, Head of CMC
Chief Corporate Development Officer and General Counsel
Senior Vice President, Human Resources
Senior Vice President, Global Regulatory Affairs & Pharmacovigilance
Vice President, Quality Assurance
Vice President, Corporate Strategy and Capital Markets
Vice President, Associate General Counsel and Secretary
Vice President, Medical Strategy
Senior Vice President, Investor Relations
Vice President, Translational Medicine
Chief Financial Officer
Chief Executive Officer and Director

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

Investor Relations Contact

Vistagen Therapeutics

Mark McPartland
Senior Vice President, Investor Relations
+1(650) 577-3606